C-H. Lee - Department of Medical Oncology, Memorial Sloan Kettering Cancer Center

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 11 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Corrigendum to "cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [eur. Urol. 86(2) (2024) 90-94]

Kelly N Fitzgerald,Chung-Han Lee,Martin H Voss, Maria I Carlo,Andrea Knezevic,Laura Peralta, Yingbei Chen,Robert A Lefkowitz,Neil J Shah,Colette N Owens,Deaglan J McHugh, David H Aggen,Andrew L Laccetti,Ritesh R Kotecha,Darren R Feldman,Robert J Motzer

European urology (2024)

引用0浏览0WOS引用

1912Tip STELLAR-304: A Randomized Phase III Study of Zanzalintinib (XL092) and Nivolumab in Non-Clear Cell Renal Cell Carcinoma (Nccrcc)

S.K. Pal,T.B. Powles,R. Kanesvaran,C-H. Lee, M. Liu, Z. Wang, A. Bhatt, P. Patel,C. Suarez Rodriguez

Annals of Oncology (2023): S1028-S1029

引用0浏览0引用

1448O Phase II KEYNOTE-B61 Study of Pembrolizumab (pembro) + Lenvatinib (lenva) As First-Line Treatment for Non-Clear Cell Renal Cell Carcinoma (Nccrcc)

L. Albiges,H.P. Gurney, V. Atduev, C. Suárez,M.A. Climent Duran,D. Pook,P. Tomczak, P. Barthelemy,J-L. Lee, T. Nalbandian,V. Stus, T. Ferguson,P. Wiechno,E. Gokmen,L. Lacombe,C. Gedye, R. Perini, M. Sharma, C. Li,C-H. Lee

Annals of Oncology (2022)

引用0浏览0引用

Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) plus lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)

L. Albiges,H. P. Gurney, V. Atduev,C. Suarez,M. A. Climent Duran,D. Pook,P. Tomczak,P. Barthelemy,J-L. Lee, T. Nalbandian,V. Stus, T. Ferguson,P. Wiechno,E. Gokmen,L. Lacombe,C. Gedye,R. Perini, M. Sharma, C. Li,C-H. Lee

ANNALS OF ONCOLOGYno. 7 (2022): S1204-S1204

引用0浏览0引用

719P Correlative Serum Biomarker Analyses: Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) in a Phase Ib/II Trial in Advanced Renal Cell Carcinoma (RCC)

C-H. Lee,Y. Adachi,H. Ikezawa, S. D. Li,Y. Funahashi,Y. Minoshima,P. Kubiak,R. Perini,M. Ren,A. D. Smith,R. J. Motzer

Annals of oncology（2020）

引用2浏览0引用

ENTRATA: Randomized, Double-Blind, Phase II Study of Telaglenastat (tela; CB-839) + Everolimus (E) Vs Placebo (pbo) + E in Patients (pts) with Advanced/metastatic Renal Cell Carcinoma (Mrcc)

R. J. Motzer,C-H. Lee,H. Emamekhoo,M. Matrana,I. Percent,J. J. Hsieh,A. Hussain,U. N. Vaishampayan, R. Graham, S. Liu,S. McCune,M. Shaheen, H. Parmar, Y. Shen, S. H. Whiting,N. M. Tannir

Annals of Oncology（2019）

引用26浏览0引用

Correlative Analyses of Serum Biomarkers and Efficacy Outcomes in the Randomized Phase II Trial of Lenvatinib (LEN), Everolimus (EVE), or LEN+EVE in Patients with Metastatic Renal Cell Carcinoma

C-H. Lee,R. J. Motzer,H. Glen,M. D. Michaelson,J. Larkin,Y. Minoshima,M. Kanekiyo,R. Dairiki,P. Sachdev,C. E. Dutcus,Y. Funahashi,M. H. Voss

Annals of Oncology（2018）

引用3浏览0WOS引用

A Phase 1b/2 Trial of Lenvatinib Plus Pembrolizumab in Patients with Renal Cell Carcinoma

Chung-Han Lee,Vicky Makker,Drew Rasco,Matthew Taylor,Corina Dutcus,Robert Shumaker,Emmett Schmidt,Daniel E. Stepan,Di Li, Louise Young,Robert Motzer

Annals of Oncology（2017）

引用21浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn